Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02198651 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
A Phase 4 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 149
- Enrollment target
NCT02198651 is a Phase 4 study that has completed, run by AbbVie. The registered enrollment target is 149 participants.
The verdict
NCT02198651, a Phase 4 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 149 participants
- Enrollment target
Study Summary
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.
Interventions
- OTHER Placebo
- BIOLOGICAL Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2015-01-05 |
| Est. Completion | 2018-08-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02198651
The ClinicalTrials.gov registry entry for NCT02198651 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02198651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02198651 about?
NCT02198651 is a clinical study titled "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects". The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled...
What is the current status of trial NCT02198651?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2015-01-05. Estimated completion is 2018-08-08.
What interventions are being tested in trial NCT02198651?
The interventions under investigation include: Placebo (OTHER), Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02198651?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.